UFC welterweight Viscardi Andrade was issued a two-year suspension from USADA after testing positive for stanozolol and its metabolites, 163-hydroxy-stanozol and 3’-hydroxy-stanozol following an out-of-competition test.
Andrade, 33, was a contestant on the second season of The Ultimate Fighter. He had a 3-1 record in the UFC including a win in his last fight in Brisbane, Australia.
Andrade’s period of ineligibility began on March 20, 2016, a day after his last bout and when the results of his out-of-competition test were discovered. The flagged test occurred on March 7, 2016.
Via USADA’s announcement:
Andrade’s two-year period of ineligibility began on March 20, 2016, the day after his most recent bout, a victory, at the UFC Fight Night event in Brisbane, Australia, on March 19, 2016. Per the UFC Anti-Doping Policy, an Anti-Doping Policy Violation occurring during, or in connection with, a bout may, upon the decision of UFC, lead to disqualification of all the athlete’s results obtained in that bout. Here, because Andrade’s violation resulted from a sample collection that occurred prior to his bout, all information surrounding Andrade’s positive test and sanction has been provided to UFC to make the determination concerning his competition results.
Since there is no athletic commission in Australia and the UFC regulates itself there, the UFC will determine whether Andrade’s win will be overturned.
Payout Perspective:
It doesn’t appear that Andrade will appeal this ruling. Stanozol is an anabolic steroid used in PEDs and is banned from use per the UFC Anti-Doping Policy. The discovery of his out-of-competition test also reveals the continuing issue with the drug policy in that tests prior to a fight are not known until after the fight takes place. This is an overarching issue that should be addressed.
Leave a Reply